Ginkgo Bioworks Holdings Inc. Class A (DNA)
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $483.54M
- EPS (TTM)
- -$4.24
- Dividend yield
- None
- 52-week range
- 5.37 – 18.22
- Day range
- 7.39 – 8.28
- Volume / Avg
- 2.50M / 2.53M
- Beta
- —
- Shares outstanding
- 53.94M
52-week range
DNA stock today
Shares of Ginkgo Bioworks (DNA) finished lower on Nov 20 at $7.46, a drop of 9.02% or $0.74 per share, versus the S&P 500's 3.70% decline. Shares are 59.1% below their 52-week high of $18.22, set on Oct 6, 2026 and 38.9% above the 52-week low of $5.37, near the bottom of the past year's range. DNA is down 10.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 8.7%.
Ginkgo Bioworks has posted a net loss over the last twelve months (EPS of -$4.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Ginkgo Bioworks
Company profileGinkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Jason Kelly Ph.D.
- Headquarters
- Boston, MA
- Employees
- 485
- IPO year
- 2021
- Website
- ginkgo.bio
Financial highlights
Full financialsIn fiscal 2025, Ginkgo Bioworks generated $170.2 million in revenue, down 25.1% from fiscal 2024, its first annual decline since 2024. Ginkgo Bioworks reported a net loss of $312.8 million, compared with a loss of $547.0 million a year earlier. Operating margin was -185.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $170.16M | $227.04M | $251.46M | $477.71M | $313.84M |
| Growth | -25.06% | -9.71% | -47.36% | +52.21% | +309.40% |
| Net income | $-312.76M | $-547.03M | $-892.87M | $-2.10B | $-1.83B |
| EPS (diluted) | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-1.39 |
Analyst forecast
ForecastConsensus (3 analysts)
underperform
Avg. price target
$8.00+7.24%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.45 vs $-0.58
- Surprise
- -150.00%
DNA news
All DNA news- Is Anthropic’s IPO a Good Reason to Buy Ginkgo Bioworks Right Now?Nasdaq
- Ginkgo Bioworks: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Ginkgo Bioworks (DNA) Q3 2026 Earnings Call TranscriptNasdaqDNA, BF.A
- Ginkgo Bioworks Holdings GAAP EPS of -$0.64 beats by $0.22, revenue of $27.7M beats by $6.19MSeeking Alpha
- Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company NovoBusiness Wire
- Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%.NasdaqACHR, TDOC, ARKK, ZM
- Ginkgo Bioworks Holdings Consensus Price Target Raised 14.29% to $8.16Nasdaq
- Araceli Biosciences und Ginkgo Bioworks ermöglichen die zelluläre Bildgebung in großem Maßstab für das „Lab-in-the-Loop"-System von NebulaPR Newswire
Ginkgo Bioworks peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs DNA |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs DNA |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs DNA |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs DNA |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs DNA |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs DNA |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs DNA |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs DNA |
Indexes, lists and sector
Ginkgo Bioworks stock FAQ
What is Ginkgo Bioworks's stock price today?
DNA last traded at $7.46 as of Nov 20, 4:00 PM EST, down 9.02% on the day. Prices are delayed at least 15 minutes.
Does Ginkgo Bioworks pay a dividend?
No. Ginkgo Bioworks does not currently pay a regular cash dividend.
Who is Ginkgo Bioworks's CEO?
Dr. Jason Kelly Ph.D. is the chief executive officer of Ginkgo Bioworks Holdings Inc. Class A, which has about 485 employees.
Has DNA ever split its stock?
Yes. The most recent DNA stock split was a 1-for-40 split on Aug 20, 2024.
What is the DNA 52-week high?
The 52-week high for DNA is $18.22 and the 52-week low is $5.37. The stock is currently 59.1% below its high.